RecruitingNCT06119269
Ponatinib in Chronic Myeloid Leukemia Patients in Chronic Phase
Studying Chronic myeloid leukemia
Last synced from ClinicalTrials.gov
ℹ
Clinical trial records are synced from ClinicalTrials.gov through automated extraction.
Report missing dataKey facts
- Sponsor
- University of Pisa
- Principal Investigator
- Sara Galimberti, PhDUniversity of Pisa - Dept. Clinical and Experimental Medicine
- Intervention
- Therapeutic drug monitoring(diagnostic_test)
- Enrollment
- 100 enrolled
- Eligibility
- 18 years · All sexes
- Timeline
- 2023 – 2025
Study locations (5)
- University of Cagliari - Businco Hospital - Unit of Hematology and Bone Marrow Transplant, Cagliari, Italy
- Policlinico Milano, Milan, Italy
- University of Naples Federico II - Unit of Hematology, Naples, Italy
- Santa Chiara University Hospital, Pisa, Italy
- Ospedale S. Eugenio ASL 2 Roma, Roma, Italy
Primary source
Recruitment status, site addresses, contacts, and full eligibility criteria can change between syncs. Always verify with the trial team before planning travel or treatment.
Open NCT06119269 on ClinicalTrials.govOther trials for Chronic myeloid leukemia
Additional recruiting or active studies for the same condition.
- RECRUITINGPHASE2NCT07354074Study to Determine the Efficacy and Safety of Asciminib in Pediatric Patients With Ph+ CML-CPNovartis Pharmaceuticals
- RECRUITINGNCT07375355Real-world Study of Scemblix in the Treatment of Chronic Myeloid Leukemia in ChinaNovartis Pharmaceuticals
- ENROLLING BY INVITATIONNCT07383298Observational Study on Dose Optimization of Olverembatinib in Patients With Chronic Myeloid Leukemia in Chronic or Accelerated PhaseQian Jiang
- RECRUITINGPHASE2NCT06817720Phase II Study Assessing the Efficacy and Toxicity of Olverembatinib Monotherapy in Patients With Newly Diagnosed Chronic Myeloid Leukemia in Chronic PhaseM.D. Anderson Cancer Center
- RECRUITINGNCT07061145A Potential Relationship Between Treatment With Tyrosine Kinase Inhibitors and Erectile Dysfunction in Male Patients With Chronic Myeloid LeukemiaAzienda USL Reggio Emilia - IRCCS
- RECRUITINGPHASE2NCT06409936PEARL Study: PotEntial of Asciminib in the eaRly Treatment of CMLGruppo Italiano Malattie EMatologiche dell'Adulto
- RECRUITINGPHASE2NCT06514534Open-label Study of Asciminib for CML-CP or CML-AP Patients With T315I Mutation Who Are Resistant, Intolerant or Ineligible to Ponatinib.Novartis Pharmaceuticals
- RECRUITINGPHASE1NCT06787144ELVN-001 for the Treatment of Chronic Myeloid Leukemia With and Without T315I Mutation in Japanese ParticipantsEnliven Therapeutics